SARAH GHAMRAWI

Clinical Research Associate since December 2022, offering a total of 14 years of research experience across academic, translational, and clinical sectors. Earned a PhD in Microbiology in 2014 and specialized in the Oncology field since 2016. For 6 years, worked on high-throughput drug-screening platforms, patient sample processing, and database development.

As a CRA, conducted independent site and remote monitoring visits, site and pharmacy monitoring, maintained and updated trial master files, and assisted with and tracked regulatory submissions, investigational products, and managed site queries and communications. Holds a training certificate in ICH-GCP from ARCS.

Having been a client of Thermo Fisher products during my lab years, I am well-acquainted with the company's commitment to making the world healthier, cleaner, and safer. I am eager to bring my expertise and passion for clinical research to the role of CRA II/Senior Clinical Research Associate at Thermo Fisher Scientific. My track record of driving successful outcomes through collaborative teamwork and commitment to upholding clinical trial standards aligns perfectly with your organization's mission of advancing global healthcare through impactful research.

• Driving license: Full
• Work rights: Australian citizen
• LinkedIn: https://www.linkedin.com/in/sarahghamrawi

PhD medical students

• 2020-2021. (3 months) design and production of personalized medicine screening plates for endocrine tumors
• 2020 (4 months). Patients sample collection and processing for inflammation detection using ELISA technique- part of a clinical trial

Master II / Honours students (6 months, co-supervision)

• Jan – Oct 2018. Faculty of Pharmacy.University of Angers (co-supervision)

Master I graduates (3 months)

• Apr – July 2014. M1 Innovative technologies.
• Undergraduate students (5 weeks each)
• Apr – May 2019. 3rd year medical school. University of Angers
• Oct – Nov 2018. 3rd year medical school. University of Angers
• Mar – Apr 2017. 3rd year medical school. University of Angers
• Mar – Apr 2013. Two students 3rd year medical school. University of Angers

• Applied GCP Training for Investigational Sites and Sponsor Representatives E6 (R2) Certificates 1,2 & 3. Dec2020. ARCS Australia. Sep 2022
• Certificate of Completion on ICH-GCP from Genesis Research Services Australia. Completed on 29 June 2022
• Certificate of Completion on GCP from The National Institute on Drug Abuse (NIDA) Clinical Trials Network. Obtained on 27 April 2021
• Training in animal experimentation (preclinical)- Certification for application of rodent procedures (rats and mice). Obtained on 11 December 2020. IUT Angers-Cholet. University of Angers.

Invited talks/ postersE-CONGRES SFPT (Société Française de Pharmacologie et de Thérapeutique). 15-16 June 2021.

• “Preliminary results of an ex vivo chemosensitivity testing assay combining cytarabine to medicinal plant compounds” (poster 1).
• “Development and validation of an ex vivo chemosensitivity testing automated method” (poster 2)

11th Conference of Cancéropôle Grand Ouest. Vannes, France. 30 June 2017 (Invited talk)

• Predicting the clinical response of patients with acute myeloid leukemia using ex vivo chemosensitivity cell screening.

Congres de la Société Française de Mycologie Médicale (SFMM). Reins, France. 23 May 2014 (Invited talk).Third Meeting of the ECMM/ISHAM Working Group on Fungal respiratory infections in Cystic Fibrosis. Angers, France. 6 June 2014 (Invited talk)Eighteenth Congress of the International Society for Human and Animal Mycology. Berlin, Germany. (poster)

• Cell wall modifications during conidial maturation and germination of the human pathogenic fungus Scedosporium boydii.

Cancer Research (5-year experience)

• Leukemia (CML, AML), Lung cancer (NSCLC), Sarcoma and Neuroblastoma: Chemosensitivity cell screening for personalized medicine therapy and synergy testing
• Endocrine tumors Testing synergy of various drugs with Tyrosine Kinase Inhibitors to improve patient response

Chronic kidney disease Linking between arterial remodeling, chronic inflammation and chronic kidney disease

Microbiology Research (4.5-year experience)

• · Novel antimicrobial silicones (medical device) : Test the antimicrobial activity of novel patented silicone materials against a large panel of bacteria and fungi according to ISO protocols
• · PhD project: A multifaceted study of the cell wall changes during maturation and germination of conidia of the human pathogenic filamentous fungus Scedosporium boydii (S. boydii)
• · Master II project: Virulence factors of the mucoid and non-mucoid strains of the bacterium Acinetobacter baumanii
• · Other: Co-culture of Pseudomonas aeruginosa and S. boydii

1. Jung M, Ghamrawi S, Du EY, Gooding JJ, Kavallaris M. Adv Healthc Mater. 2022 Jul 22; e2200690

2. Anthony N, Bourneau-Martin D, Ghamrawi S, Babin M, Briet M. Fundam Clin Pharmacol. 2020 Dec; 34(6): 736-742.

3. Vacher R, Lagarce L, Ghamrawi S, Laugier-Castellan D, Vial T, Bagheri H, Babin M, Briet M. Fundam Clin Pharmacol. 2020 Oct; 34(5): 623-631.

4. Abbara C, Drevin G, Férec S, Ghamrawi S, Souchet S, Robin JB, Schmidt A, Hunault-Berger M, Guardiola P, Briet M. Cancer Chemother Pharmacol. 2020 Nov; 86(5): 687-691.

5. Drevin G, Briet M, Ghamrawi S, Beloncle F, Abbara C. Forensic Sci Int. 2020 Nov; 316: 110541.

6. Ghamrawi S, Bouchara JP, Corbin A, Rogalsky S, Tarasyuk O, Bardeau JF. 2019. Materials Today Communications. 22(2020) 100716.

7. Ghamrawi S, Bouchara JP, Tarasyuk O, Rogalsky S, Lyoshina L, Bulko O, Bardeau JF. 2017. Mater Sci Eng C Mater Biol Appl. Jun 1; 75:969-979.

8. Ghamrawi S, Gastebois A, Zykwinska A, Marot A, Mabilleau G, Vandeputte P, Cuenot S, Bouchara JP. 2015. PLoS ONE 10(6): e0128680.

9. Ghamrawi S, Rénier G, Saulnier P, Cuenot S, Zykwinska A, Dutilh B, Thornton C, Faure S, Bouchara JP. 2014. PLoS ONE 9(6): e100290.

10. Vandeputte P, Ghamrawi S, Rechenmann M, Iltis A, Giraud S, Fleury M, Thornton C, Delhaès L, Meyer W, Papon N, Bouchara JP. 2014. Genome Announc. 2(5): e00988-14.

11. Kempf M, Eveillard M, Deshayes C, Ghamrawi S, Lefrançois C, Georgeault S, Bastiat G, Seifert, H, Joly-Guillou ML. 2012. Can. J. Microbiol. 58: 311–317.

12. Hamon Y, Jaillon S, Person C, Giniès J-L, Garo E, Bottazzi B, Ghamrawi S, Urban T, Subra JF, Bouchara JP, Mantovani A, Jeannin P, Delneste Y. 2012. Innate Immunity. 19(6): 611-22.

13. Marion E, Prado S, Cano C, Babonneau J, Ghamrawi S, Marsollier L. 2012. PLoS ONE 7(4): e33600.

Contacted 50 patients for a clinical trial on early COVID-19 symptoms, May 2020.

• Contacted 50 patients for a clinical study on the loss of sense of smell and taste (before this became announced to the public by national authorities).
• I was the first to complete data collection and entry among colleagues
• Reported problems to the CRA to ensure accurate data entry